C07K 14/535
Granulocyte csf
Official title: Granulocyte CSF; Granulocyte-macrophage CSF
C07K14/535 (Granulocyte csf) appears on 770 US grants and 1,040 published applications in this corpus.
Search patents in C07K- Granted patents
- 770
- Published applications
- 1,040
- Assignees
- 465
- Inventors
- 1,750
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 5 | 0 |
| 1991 | 8 | 0 |
| 1992 | 8 | 0 |
| 1993 | 7 | 0 |
| 1994 | 6 | 0 |
| 1995 | 14 | 0 |
| 1996 | 14 | 0 |
| 1997 | 22 | 0 |
| 1998 | 26 | 0 |
| 1999 | 34 | 0 |
| 2000 | 14 | 0 |
| 2001 | 22 | 5 |
| 2002 | 13 | 18 |
| 2003 | 18 | 40 |
| 2004 | 13 | 44 |
| 2005 | 13 | 30 |
| 2006 | 13 | 28 |
| 2007 | 17 | 47 |
| 2008 | 18 | 44 |
| 2009 | 27 | 32 |
| 2010 | 25 | 41 |
| 2011 | 23 | 34 |
| 2012 | 17 | 20 |
| 2013 | 30 | 50 |
| 2014 | 25 | 64 |
| 2015 | 36 | 43 |
| 2016 | 39 | 53 |
| 2017 | 29 | 39 |
| 2018 | 34 | 44 |
| 2019 | 24 | 46 |
| 2020 | 31 | 53 |
| 2021 | 19 | 52 |
| 2022 | 26 | 34 |
| 2023 | 31 | 64 |
| 2024 | 19 | 45 |
| 2025 | 30 | 42 |
| 2026 | 16 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- Genetically modified non-human animals expressing human EPO4 Aug 2026US 12,696,884 B2Institute for Research in Biomedicine (IRB)
- Methods for making stable protein compositions14 Jul 2026US 12,679,865 B2Amgen Inc.
- Heterodimeric human IgG1 polypeptides with isoelectric point modifications23 Jun 2026US 12,662,553 B2Xencor, Inc.
- Methods and compositions for treating cancer1 Oct 2026US 2026/0297152 A1
- A Vaccine Composition of Cells Expressing a Lentiviral Vector and Methods of Using27 Aug 2026US 2026/0250717 A1Meridian Therapeutics, Inc.
- Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf)20 Aug 2026US 2026/0240950 A1Partner Therapeutics, Inc.
- Fusion cytokine compositions and methods of use thereof13 Aug 2026US 2026/0232779 A1Wisconsin Alumni Research Foundation
- Recombinant oncolytic virus and use thereof16 Jul 2026US 2026/0199415 A1Joint Biosciences (Sh) Ltd.
Most cited
By later US patents
- Oligonucleotide mediated nucleic acid recombination400US 6,376,246 B1Maxygen, Inc. · 2002
- N-terminally chemically modified protein compositions and methods378US 5,824,784 AAmgen Inc. · 1998
- Site-specific homogeneous modification of polypeptides317US 4,904,584 AGenetics Institute, Inc. · 1990
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014
- Production of pluripotent granulocyte colony-stimulating factor304US 4,810,643 AKirin-Amgen, Inc. · 1989